BG
ACHN

Bellevue Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Bellevue Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-99,000
Closed -$417K – 139
2017
Q1 		$417K Sell
99,000
-141,000
-59% -$585K 0.06% 126
2016
Q4 		$991K Hold
240,000
– – 0.2% 86
2016
Q3 		$1.94M Sell
240,000
-180,000
-43% -$1.53M 0.35% 77
2016
Q2 		$3.28M Hold
420,000
– – 0.62% 52
2016
Q1 		$3.24M Buy
+420,000
New +$3.08M 0.59% 54

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Bellevue Group's ACHN Position: Q2 2017 in Review

Bellevue Group sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 99,000 shares — an estimated $417K sold.

Bellevue Group first reported a position in ACHN in Q1 2016 and held it in 5 quarters. The position peaked at $3.28M in Q2 2016. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

  • Bellevue Group reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Bellevue Group sold 99,000 Achillion Pharmaceuticals shares in Q2 2017, an estimated $417K.
  • Bellevue Group first reported a position in Achillion Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Bellevue Group's Achillion Pharmaceuticals position peaked at $3.28M in Q2 2016.
  • 129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Bellevue Group's 13F filing for Q2 2017, filed 14 Aug 2017.